Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Survival prediction in relapsed/refractory B-cell lymphoma treated with CAR-T therapy: An AI-optimized cox regression model based on CCL5, scgf-β, and TRAIL

Hu Qian, Zekai Mao, Anqi Zhang, Xiaoying Zhang, Xingcheng Yang, Juan Peng, Jiaqi Guo, Liting Chen, Hui Luo, Li Zhu, Xiaoxi Zhou, Yang Yang, Na Wang, Jue Wang, Yicheng Zhang, Jia Wei

Blood (2025) 146 (Supplement 1): 4115.

https://doi.org/10.1182/blood-2025-4115

Published: 2025

Journal Articles

Long-term follow-up results of nonremission relapsed/refractory DLBCL with CAR T-cell cocktail therapy alone or in combination with ASCT

Xiaoying Zhang, Jue Wang, Na Wang, Jia Wei, Yang Cao, Yicheng Zhang

Blood (2025) 146 (Supplement 1): 7243.

https://doi.org/10.1182/blood-2025-7243

Published: 2025

Journal Articles

Long-term follow-up reveals sustained benefit of dual CD19/CD22 CAR T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma

Juan Peng, Zekai Mao, Yang Cao, Na Wang, Jue Wang, Yang Yang, Jinghuan Xu, Fankai Meng, Liting Chen, Xia Mao, Jiaqi Guo, Xiaoxi Zhou, Yicheng Zhang, Jia Wei

Blood (2025) 146 (Supplement 1): 3712.

https://doi.org/10.1182/blood-2025-3712

Published: 2025

Journal Articles

Belumosudil is effective in patients with chronic graft-versus-host disease lasting more than two years: A retrospective single-center real-world study

Cheng Zhang, Na Wang, Xueling Ge, Panpan Feng, Peipei Li, Changqing Zhen, Xiaosheng Fang, Yujie Jiang

Blood (2025) 146 (Supplement 1): 7750.

https://doi.org/10.1182/blood-2025-7750

Published: 2025

Journal Articles

Deciphering Clonal Evolution of Immunoglobulin Heavy Chain Locus Enhances Next-Generation Sequencing-Based Measurable Residual Disease Detection in Adult B-Acute Lymphoblastic Leukemia

Yang Dai, Bei Yu, Jie Zhang, Yu Wu, Zhidong Yang, Na Wang, Tong Chen, Libo Hu, Wanqiu Yang, Shiang Huang, Ting Liu, Xiaofei Ye

Blood (2024) 144 (Supplement 1): 2840.

https://doi.org/10.1182/blood-2024-204493

Published: 2024

Journal Articles

Comparison of the Efficacy and Adverse Effects of Recipient-Derived Versus Donor-Derived CAR-T Cell Therapy for Post-Transplant Relapse in B-ALL

Lichao Liu, Ruihao Huang, Yongxian Hu, Sanfang Tu, Na Wang, Hai Yi, Qiuying Gao, Jian Zhou, Xiaoqi Wang, Cheng Zhang, Xi Zhang

Blood (2024) 144 (Supplement 1): 3469.

https://doi.org/10.1182/blood-2024-207676

Published: 2024

Journal Articles

Genetic Insusceptibility Mediated Inflammation Contributes to Bortezomib-Induced Peripheral Neuropathy

Jialin Zhou, Hanheng Mai, Yunqing Liu, Na Wang, Xiao Lv, Xin Wang, Lili Feng

Blood (2024) 144 (Supplement 1): 1961.

https://doi.org/10.1182/blood-2024-201966

Published: 2024

Journal Articles

Functional Diversification and Dynamics of CAR-T Cells in B-ALL Patients

Blood (2023) 142 (Supplement 1): 4851.

https://doi.org/10.1182/blood-2023-178624

Published: 2023

Journal Articles

Radiation Prior to Chimeric Antigen Receptor T-Cell Therapy Is an Optimizing Bridging Strategy in Relapse/Refractory Aggressive B-Cell Lymphoma

Qiuxia Yu, Xiaoying Zhang, Na Wang, Liang Huang, Chunrui Li, Yicheng Zhang, Jianfeng Zhou, Gaoxiang Wang, Yang Cao

Blood (2022) 140 (Supplement 1): 10311–10312.

https://doi.org/10.1182/blood-2022-165174

Published: 2022

Journal Articles

MIP3α As an Early Prognostic Predictor for Patients with B-Cell Malignancies Receiving CD19/CD22-Redirected CAR T-Cell Cocktail Therapy

Jin Jin, Jiali Cheng, Na Wang, Liang Huang, Xiaoxi Zhou, Liting Chen, Hui Luo, Tianjiao Liu, Jiao Meng

Blood (2022) 140 (Supplement 1): 10265–10266.

https://doi.org/10.1182/blood-2022-156710

Published: 2022

Journal Articles

Thyroid Complications Negatively Affect Therapeutic Response and Survival in Waldenstrom Macroglobulinaemia/ Lymphoplasmacytoid Lymphoma

Xinting Hu, Hua Wang, Hongzhi Xu, Xin Liu, Ying Li, Xianghua Wang, Na Wang, Dai Yuan, Huiting Qu, Ya Zhang, Xin Wang

Blood (2021) 138 (Supplement 1): 4513.

https://doi.org/10.1182/blood-2021-149677

Published: 2021

Journal Articles

Anti CD19/22 Cocktail CAR T-Cell Therapy Can Improve the Outcomes of Patients with TP53-Mutated Relapsed/Refractory B-Cell Lymphoma

JIA Wei, MDPhD, Min Xiao, Zekai Mao, Na Wang, MD PhD, Chunrui Li, MDPhD, Yang Cao, Weimin Sun, Yi Xiao, Chaojiang Gu, Shangkun Zhang, PhD, Yicheng Zhang, Tongcun Zhang, PhD, Jianfeng Zhou, MD PhD, Liang Huang, MD

Blood (2020) 136 (Supplement 1): 43.

https://doi.org/10.1182/blood-2020-138947

Published: 2020

Journal Articles

CD19/CD22 CAR-T Cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory B-Cell Lymphomas

Yang Cao, Yi Xiao, Na Wang, MD PhD, Gaoxiang Wang, MDPhD, Xiaoxi Zhou, MDPhD, Liang Huang, MD, Liting Chen, PhD, Min Xiao, MD PhD, Tongcun Zhang, PhD, Yicheng Zhang, Jianfeng Zhou, MD PhD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-140308

Published: 2020

Journal Articles

Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy

Wenyue Cao, Jia Wei, Na Wang, Hao Xu, Min Xiao, Lifang Huang, Yang Cao, Chunrui Li, Yi Xiao, Chaojiang Gu, Shangkun Zhang, Dengju Li, Yichen Zhang, Tongcun Zhang, Jianfeng Zhou, Liang Huang

Blood (2020) 136 (4): 516–519.

https://doi.org/10.1182/blood.2020004907

Published: 2020

Includes: Supplemental data

Journal Articles

Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies

Blood (2020) 135 (1): 17–27.

https://doi.org/10.1182/blood.2019000017

Published: 2020

Includes: Supplemental data

Journal Articles

CAR22/19 Cocktail Therapy for Patients with Refractory/Relapsed B-Cell Malignancies

Liang Huang, MDPhD, Na Wang, MD PhD, Yang Cao, Chunrui Li, MDPhD, Yi Xiao, MD PhD, Min Xiao, MD PhD, Xiaoxi Zhou, MD, PhD, Gaoxiang Wang, MDPhD, Zhenya Hong, MD, PhD, Miao Zhen, MD, PhD, Weixu Meng, MD PhD, Bin Zhang, PhD, Yicheng Zhang, MDPhD, Guido Marcucci, Tongcun Zhang, PhD, Jianfeng Zhou, PhD

Blood (2018) 132 (Supplement 1): 1408.

https://doi.org/10.1182/blood-2018-99-113714

Published: 2018

Journal Articles

Rituximab-Induced Acute Thrombocytopenia in a Patient with Relapsed Follicular Lymphoma

Jiang Yujie, MD, Na Wang, MD, Dai Yuan, MD, Huiting Qu, MD, Lili Feng, MD PhD, Juan Fan, MD, Xin Wang, MD PhD

Blood (2018) 132 (Supplement 1): 5343.

https://doi.org/10.1182/blood-2018-99-117608

Published: 2018

Journal Articles

Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells Following Autologous HSCT in Patients with B-NHL

Yang Cao, Na Wang, MD PhD, Gaoxiang Wang, MD PhD, Yi Xiao, MD PhD, Liang Huang, MD PhD, Chunrui Li, MD PhD, Min Xiao, MD PhD, Tongcun Zhang, PhD, Yicheng Zhang, MD PhD, Jianfeng Zhou, MD PhD

Blood (2018) 132 (Supplement 1): 2054.

https://doi.org/10.1182/blood-2018-99-113827

Published: 2018

Journal Articles

Medium-Dose VP-16 Intensified Conditioning Regimen Is Effective in Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia

Feifei Sun, Xiaosheng Fang, PhD, Jiang Yujie, MD, Xiaohui Sui, Xin Liu, Xianghua Wang, Ying Li, Na Wang, MD, Changqing Zhen, Huiting Qu, MD, Juan Fan, MD, Hongzhi Xu, Xin Wang, MD PhD

Blood (2018) 132 (Supplement 1): 5781.

https://doi.org/10.1182/blood-2018-99-117825

Published: 2018

Journal Articles

Heterogeneous Responses Among Ph + -B-ALLs to Imatinib with NRAS Mutant Being One Mechanism of Complete Resistance

Xiaoyu An, Jinping Liu, Na Wang, MD PhD, Di Wang, MD PhD, Liang Huang, MD PhD, Jie Cai, PhD, Demin Zhou, PhD, Henry Li, PhD

Blood (2018) 132 (Supplement 1): 5801.

https://doi.org/10.1182/blood-2018-99-115516

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Survival prediction in relapsed/refractory B-cell lymphoma treated with CAR-T therapy: An AI-optimized cox regression model based on CCL5, scgf-β, and TRAIL

Long-term follow-up results of nonremission relapsed/refractory DLBCL with CAR T-cell cocktail therapy alone or in combination with ASCT

Long-term follow-up reveals sustained benefit of dual CD19/CD22 CAR T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma

Belumosudil is effective in patients with chronic graft-versus-host disease lasting more than two years: A retrospective single-center real-world study

Deciphering Clonal Evolution of Immunoglobulin Heavy Chain Locus Enhances Next-Generation Sequencing-Based Measurable Residual Disease Detection in Adult B-Acute Lymphoblastic Leukemia

Comparison of the Efficacy and Adverse Effects of Recipient-Derived Versus Donor-Derived CAR-T Cell Therapy for Post-Transplant Relapse in B-ALL

Genetic Insusceptibility Mediated Inflammation Contributes to Bortezomib-Induced Peripheral Neuropathy

Functional Diversification and Dynamics of CAR-T Cells in B-ALL Patients

Radiation Prior to Chimeric Antigen Receptor T-Cell Therapy Is an Optimizing Bridging Strategy in Relapse/Refractory Aggressive B-Cell Lymphoma

MIP3α As an Early Prognostic Predictor for Patients with B-Cell Malignancies Receiving CD19/CD22-Redirected CAR T-Cell Cocktail Therapy

Thyroid Complications Negatively Affect Therapeutic Response and Survival in Waldenstrom Macroglobulinaemia/ Lymphoplasmacytoid Lymphoma

Anti CD19/22 Cocktail CAR T-Cell Therapy Can Improve the Outcomes of Patients with TP53-Mutated Relapsed/Refractory B-Cell Lymphoma

CD19/CD22 CAR-T Cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory B-Cell Lymphomas

Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy

Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies

CAR22/19 Cocktail Therapy for Patients with Refractory/Relapsed B-Cell Malignancies

Rituximab-Induced Acute Thrombocytopenia in a Patient with Relapsed Follicular Lymphoma

Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells Following Autologous HSCT in Patients with B-NHL

Medium-Dose VP-16 Intensified Conditioning Regimen Is Effective in Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia

Heterogeneous Responses Among Ph + -B-ALLs to Imatinib with NRAS Mutant Being One Mechanism of Complete Resistance

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only